Table 1.

Incidence and severity of EAP in d3tx B6AF1 mice that received different numbers of Tregs from donors with or without prostates

			EAP in d3tx recipients
Treg donor	Treg donor treatment (duration)	Treg nos.	Incidence, % (no.)	Severity*
None	–	–	53 (17)	2.3 ± 0.2
Male 1	–	3 × 104	56 (9)	1.9 ± 0.4
Male 2	–	1 × 105	37 (8)	1.8 ± 0.6
Male 3	–	3 × 105	0 (14)	–
Female 1	–	3 × 104	67 (12)	2.2 ± 0.3
Female 2	–	1 × 105	67 (12)	2.4 ± 0.3
Female 3	–	3 × 105	26 (23)	1.6 ± 0.2
Female 4	–	1 × 106	0 (5)	–
Male 4	NOr	3 × 105	45 (11)	1.9 ± 0.5
Male 5	NOr	1 × 106	0 (16)	–
Male 6	NOr-DHT (6 wk)	3 × 105	11 (9)	0.5 ± 0
Male 7	NOr-DHT (2 wk)	3 × 105	6 (16)	2.0 ± 0
Male 8	NOr-DHT (1 wk)	3 × 105	24 (21)	1.6 ± 0.4
Male 9	NOr-ATx-DHT†	3 × 105	0 (20)	–
Female 5	DHT-prostate‡	3 × 105	8 (12)	2.0 ± 0
Female 6	DHT‡	3 × 105	58 (12)	1.8 ± 0.3
Female 7	Prostate‡	3 × 105	30 (10)	2.0 ± 0.6

– indicate none.

^*Mean ± SD of mice with disease

^†Six-week-old NOr males were thymectomized and received implants of DHT pellets for 2 weeks

^‡Six-week-old females received implants of prostate or DHT pellet or both for 2 weeks